{
    "organizations": [],
    "uuid": "373045ec1fa1d305ed88c26cceb6e3f7e2b92ca2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-astellas-says-cytomegalovirus-vacc/brief-astellas-says-cytomegalovirus-vaccine-did-not-meet-its-primary-or-secondary-endpoints-in-phase-3-helios-clinical-trial-idUSASB0C1N1",
    "ord_in_thread": 0,
    "title": "BRIEF-Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News  15 AM / in 5 minutes BRIEF-Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​ Reuters Staff 1 Min Read \nJan 22 (Reuters) - Astellas Pharma Inc: \n* ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS \n* ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​ \n* ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T10:13:00.000+02:00",
    "crawled": "2018-01-22T10:24:31.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "minute",
        "say",
        "cytomegalovirus",
        "vaccine",
        "asp0113",
        "meet",
        "primary",
        "secondary",
        "endpoint",
        "phase",
        "helios",
        "clinical",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "astellas",
        "pharma",
        "inc",
        "astellas",
        "vical",
        "announce",
        "result",
        "phase",
        "trial",
        "cytomegalovirus",
        "vaccine",
        "asp0113",
        "hematopoietic",
        "stem",
        "cell",
        "transplant",
        "recipient",
        "astellas",
        "pharma",
        "inc",
        "say",
        "generally",
        "well",
        "tolerated",
        "reaction",
        "commonly",
        "reported",
        "adverse",
        "astellas",
        "pharma",
        "asp0113",
        "meet",
        "primary",
        "secondary",
        "endpoint",
        "phase",
        "helios",
        "clinical",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}